NCT01717170

Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: University of Nebraska · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

In the STOP-UVEITIS study, we propose to evaluate the safety, tolerability, and bioactivity of two doses of Tocilizumab (4mg/kg and 8mg/kg), administered monthly, in patients with non-infectious intermediate, posterior, or panuveitis.

Conditions

• Intermediate Uveitis
• Posterior Uveitis
• Pan-uveitis

Interventions

Type	Name	Description
DRUG	Tocilizumab	Tocilizumab (4 mg/kg or 8 mg/kg)

Timeline

• Start date: 2013-03-01
• Primary completion: 2017-06-01
• Completion: 2017-12-01
• First posted: 2012-10-30
• Last updated: 2017-04-28

Locations

1 site across 1 country: United States